- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
Varlilumab (Anti-TNFRSF7 / CD27)
製品コードA2323 別名: CDX-1127
Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD.
質量管理及び製品安全説明書
現在のバッチを見る：
A232301
純度：
99%
タンパク質濃度： 11.546mg/ml
内毒素： ＜1EU/mg
99
CD markers阻害剤の選択性比較
生物活性
| 製品説明 | Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. |
|---|
製品説明
| CAS No. | 1393344-72-3 |
|---|---|
| Molecular Weight | 150 kDa |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Isotype | Human IgG1 |
| Source | CHO |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
| Shipping | Shipped under low temperature conditions |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
各種クローンの論文数比較
*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。
臨床試験
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT03688178 | ACTIVE_NOT_RECRUITING | Drug: Temozolomide | Glioblastoma | Annick Desjardins, MD | 2020-08-26 | PHASE2 |
| NCT04941287 | ACTIVE_NOT_RECRUITING | Drug: Cobimetinib|Drug: Varlilumab | Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Liver Carcinoma | National Cancer Institute (NCI) | 2021-12-15 | PHASE2 |
| NCT03038672 | ACTIVE_NOT_RECRUITING | Drug: Varlilumab | ALK-Positive Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Mucocutaneous Ulcer; HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Intravascular Large B-Cell Lymphoma; Large B-Cell Lymphoma With 11q Aberration; Large B-Cell Lymphoma With IRF4 Rearrangement; Plasmablastic Lymphoma; Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System; Primary Effusion Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Gray-Zone Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent Lymphomatoid Granulomatosis; Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Gray-Zone Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | National Cancer Institute (NCI) | 2018-12-21 | PHASE2 |
| NCT02924038 | TERMINATED | Glioma; Malignant Glioma; Astrocytoma, Grade II; Oligodendroglioma; Glioma, Astrocytic; Oligoastrocytoma, Mixed | Nicholas Butowski | 2017-04-03 | PHASE1 | |
| NCT04081688 | TERMINATED | Drug: Atezolizumab 1200 MG in 20 ML Injection|Drug: Varlilum | Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 | Rutgers, The State University of New Jersey | 2019-09-11 | PHASE1 |
| NCT03307746 | COMPLETED | Drug: Varlilumab | B Cell Lymphoma | University Hospital Southampton NHS Foundation Trust | 2017-11-23 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-05-22)
技術サポート
ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。
他に質問がある場合は、お気軽にお問い合わせください。
* 必須
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間